Spacer
NeurogenxAS417R
Spacer
PresentBannerCU317
Spacer
INGBannerE215
Podiatry Management Online


Facebook

Podiatry Management Online
Podiatry Management Online


AmerXKitBannerGY517

Search

 
Search Results Details
Back To List Of Search Results

03/27/2014    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Arnold Ross, DPM, Burton J. Katzen, DPM


 



I enjoyed the three-year program. Unfortunately, the plan to have more grads was questionably calculated. In California, the old CCPM had approximately 100 students per class with a podiatric hospital and fully functioning orthotic lab. Now, we have two schools in California with approximately 100 students or less in total, and no hospital or orthotic lab in either.


 


Arnold Ross, DPM, Los Angeles, CA, asross1@juno.com



 


I cannot believe that anyone in our profession could possibly vote for the 3-year podiatry curriculum. Before I looked at the results, I thought the voting would be less than 1%. First of all, as one of my colleagues stated, there is way too much to learn for even four years. Also, for those of us who have been around for over 40 years, if you think we were looked down upon by our medical colleagues and the general public in the past, this would be a public relations disaster, not to mention a credentialing disaster for hospitals, etc.


 


One viable alternative would be a 6-year college/podiatry degree program like Hopkins and several medical schools have, or at least I know had in the past. This would especially be a viable alternative for schools affiliated with undergraduate schools like Temple. Also, we're the only profession that is trying to force every graduate into becoming a surgeon with a 3-year residency to even get a license in most states. This is extremely detrimental and costly to the students wishing to provide for patients needing other types of care, and for our profession in general.


 


Burton J. Katzen, DPM, Temple Hills, MD. DrburtonK@aol.com

Other messages in this thread:


05/19/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2


RE: Radiesse is Now Available for Podiatrists


From: Bret Ribotsky, DPM


 


As was first reported weeks ago in PM News, there was the inability of DPMs to purchase Radiesse to use for injections for pedal soft tissue temporary augmentation (PSTTA). This issue has been resolved. After meeting with the new CEO of Merz and his leadership team, what should have been a simple process became as difficult as walking through a minefield. It began with corporate compliance and federal regulations that were in place to make it unable to sell to a provider (DPM) where no FDA-approved indication existed within our scope of practice. 


 


This is behind us now. Any DPM who has received approved training, such as attending a DERMFOOT workshop, is now eligible to purchase this product. It is hoped that a series of training seminars can be done nationally to give this opportunity to all who are interested.


 


Bret Ribotsky, DPM, Boca Raton, FL

05/06/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2


RE: Kudos to Chris Bryant, DPM


From: Craig Nilsen


 


During a recent sales trip to Kentucky (KY), one of my sales associates went for a jog in the morning and rolled his ankle during the jog. We went to KY to work a booth at the KPMA conference for Henry Schein. As he was hobbling around the exhibit hall Chris Bryant, DPM came into our booth and asked if he could have a look at my associate's foot. Upon removing his shoe, you could see his ankle was very swollen.


 


At that point, Dr. Bryan personally drove my associate to his office which was just a couple of miles away and gave him physical therapy, applied a compression bandage, put him in a CAM walker, and then brought him back to the meeting. Dr. Bryant really went above and beyond anyone's expectations. Thanks again, Dr. Bryant.


 


Craig Nilsen, Henry Schein Medical

04/21/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Joel Lang, DPM


 


Everyone take a breath. People are going to be people and we are in the people business. Everyone has personal faults and events over which they have no control. That’s why some patients will miss their first appointments. Sometimes our schedule runs late and patients are inconvenienced. I don’t see any doctors offering to treat them for free to compensate them for their inconvenience. So let’s be realistic. Missed appointments will happen, but they are a very tiny fraction of our patient experiences. Don’t focus on the “small stuff”.


 


In the long run, those misses will have little effect on your bottom line and may give you an occasional “break” during the day, that you can probably use. If someone misses, forgive them as you would like to be forgiven for your lateness in treating them. Making everyone follow some rule or having patients give credit card numbers to doctors they don’t even know is an unnecessary intrusion. It punishes the many for the actions of the few.


 


Accept the fact that people are imperfect; accept their foibles and do the best for the patient in front of you. Success will follow. Expecting perfection will result in chronic disappointment – not a good way to conduct your life or practice.


 


Joel Lang, DPM (retired), Cheverly, MD

04/20/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Paul Busman DPM, RN


 


"Those who refuse to give us a credit card do not get an appointment. This is a real simple solution."


 


This is not such a great solution. Believe it or not, there are still a lot of people who don't have credit cards at all! This includes many older potential patients who don't trust those newfangled things. There are also many individuals who, for various reasons, don't qualify for a card but who would otherwise be excellent, deserving patients. Shouldn't these people have access to quality footcare too?  


 


Paul Busman DPM, RN, Frederick, MD

04/18/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2


RE: High Cost of Drugs (George Jacobson, DPM)


From: Kathleen Neuhoff, DPM


We e-prescribe and give each patient a written script also. This gives them a shopping choice and eliminates the weekend calls when the pharmacy cannot find the prescription! 



Kathleen Neuhoff, DPM, South Bend, IN

04/14/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Donald R Blum, DPM, JD


 


The responsibility for controlling one's medical cost rests with the patient (beneficiary). For medications I use on a regular basis (90-day prescriptions), I research the cost. My sources are the website for my prescription plan and GoodRx.com. When I ask my doctor for a refill, I have the pharmacy where I want the Rx to go and make the request. Additionally, I have the app for GoodRx.com on my phone just in case my doctor wants to give to me a new Rx so I can explore the "CASH" price prior to getting the prescription.


 


I also look up the cost of prescriptions. I am able to show the patient a cash price for that drug as well as the different prices at the different pharmacies in the area. The patient can then decide what pharmacy they want based on cost. I am a little surprised that the State of NY requires only ePrescribe; I thought that was related to CMS, not to the state.


 


Disclosure: I have no financial interest in goodrx.com. There are also many discount Rx services.


 


Donald R Blum, DPM, JD, Dallas, TX

04/11/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2


RE: High Cost of Drugs (George Jacobson, DPM)


From: Elliot Udell,DPM


 


Let’s open another can of worms with regard to the cost of drugs. In New York State, doctors are required by law to e-prescribe. My allergist e-prescribed some medication for me. I paid for it at the local pharmacy, only to find out that I could have saved a significant amount of money had I gone to another drug store. The way e-prescribing is set up with insurance companies is that the pharmacy will not give you the final price of the medication until they process the prescription. In order to price compare, I would have had to ask my doctor to send off the prescription to other pharmacies, which he cannot do using his program. This set-up is another example of how our government has set up prescription benefits in a way that does not help the consumer.


 


Elliot Udell, DPM, Hicksville, NY

04/10/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Ira Baum, DPM


 


Dr. Jacobson's remarks were excellent. I applaud his comments and understand the work he put in to collect the data and analyze it to present this valuable information on the comparative costs of many medications. If he has this information available in an easy format, would he be willing to share it?


 


Ira Baum, DPM, Naples, FL

04/07/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: George Jacobson, DPM


 


Yes, it is absolutely ridiculous and scandalous. The light should be shined publically on the very examples discussed here. I study the costs and review the generic formularies at Walmart ($4 list), Publix (free list), Target...  Indomethacin, terbinafine, meloxicam, naproxen, flucinolone, and cephalexin can be purchased for $4 or less. This is especially advantageous for the uninsured and sometimes less than some co-payments. I also walk by and look at the OTC products at different stores near my office, so I know what is available and the cost.  


 


You can get 25% urea cream (Heel Balm) at Walmart for $4.99 and the same product is $9.99 at Walgreens. Clotrimazole 1% is $1.00 at most "dollar stores" which can cost $10-$15 at most pharmacies. I keep hydrocortisone 1% (also $1) and the clotrimazole 1% in the office and make 100% by charging $2.00. Patients appreciate that I am concerned about their medical expenses. By the way, the Walmart's "Antifungal Liquid" 1oz (30ml) is 25% undecylenic acid and costs $5.99. I have had patients purchase 25% undecylenic acid for $40 from their former podiatrist.


 


George Jacobson, DPM, Hollywood, FL

03/14/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Paul Kesselman, DPM


 


While it is true that Medicare does not normally cover orthotics, the "read between the lines" implication of this proposal is that DPMs, MDs, and DO physicians are not trained to dispense foot orthotics. I can think of just a few things that a plaintiff's counsel might do with that at a trial where the patient alleges they were injured from your orthotic device. 


 


This is regardless of whether you care or don't care whether third party payers cover the device. Whether you agree with this philosophy or not, the jury just hearing this will...


 


Editor's note: Dr. Kesselman's extended-length letter can be read here.

03/06/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Joel Lang, DPM


 


As a financial planner, I can state that it almost never is worthwhile to lease a car. Ownership, in the long run, is a far better financial choice. A car is a guaranteed depreciating asset. Leasing requires you to pay all the depreciation without the benefit of eventual ownership. I don’t know what you drive now, but if it is too old to fix, you apparently keep cars for a long time. Very smart. If the vehicle is otherwise sound, fix it and drive it for a few more years. If not, purchase another one; one that you like, not what your patient will admire. Purchasing a 2-3 year old car, perhaps one that just came off a lease, is financially smart because someone else just paid the major portion of the depreciation.


 


No one is impressed with the car you drive. In a recent discussion with a New York Mercedes dealer, I was told that 90% of their cars are leased, not purchased. That is because the customers who want them cannot afford the purchase and see leasing as a false saving – lower monthly payments; except the payments go on forever. Save the money you potentially waste on cars and take your family on a vacation – create memories. The wealthiest people I know do not flaunt their net worth. They live quiet, comfortable lives without regard to their “public image”.


 


Joel Lang, DPM (retired), Cheverly, MD

03/03/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: David S. Wolf, DPM, Philip J. Shapiro, DPM


 


I think the question should be...”Do patients judge us on what type of professional experience they have after leaving our office?” (Not what type of car we drive). Were they treated with real concern and acknowledgement, did the staff show empathy, will they recommend you to their PCP and friends?


 


David S. Wolf, DPM (retired), Houston, TX


 


Regarding Dr. Elliot Udell’s question about the car that we drive and what our patients might think of us for our choice, there was a time when that truly mattered. That time period began in the 1950s and represented the values of those doctors from that generation, as well as the perceptions of the general public until around 1980. By that time, I started to notice in the physicians’ parking lot at my hospital that the physicians (MD, DO, DPM) were driving everything from high-end luxury vehicles to economy-level vehicles. In my own private, solo practice, no one seemed to notice, or at least comment on what I was driving, and that ranged from high-end in the 1980s to mid-level by the 1990s. So, as the saying goes, drive what you like and like what you drive. Patients care how much you care about them, and not what you drive.


 


Philip J. Shapiro, DPM, Ormond Beach, FL

01/30/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Don Peacock, DPM, MS


 


I am a strong advocate of epidermal nerve biopsies. They play a vital role in my clinical practice. The procedure has many advantages over traditional ways of monitoring small nerve fiber neuropathy. The procedure is minimally invasive and can give quantifiable empirical data to prove the presence of unmyelinated small nerve fiber neuropathy. It has the added benefit of greater sensitivity compared to  traditional nerve studies. The study is repeatable and can be used as a marker for instituting therapeutic modalities and monitoring nerve regeneration. I would not want to practice without the use of these studies. Our neuropathy patients are some of the most miserable patients with respect to their noxious pain levels. These patients need to be treated aggressively and completely. This absolutely includes the use of epidermal nerve biopsy. 


 


All procedures have potential risks, and we need to take into account certain health aspects that are potential contra-indications. Diabetics with adequate circulation should not be excluded from a minimally invasive epidermal nerve biopsy. If cellulitis occurs, treat the complication accordingly. For the majority of our neuropathy patients, the information received from the epidermal nerve biopsies represents a valuable aspect of treating them along with more aggressive interventions such as decompression surgery, etc. 


 


Don Peacock, DPM, MS. Whiteville, NC

01/27/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2A



From: Elliot Udell, DPM


 


Dr. Hurchik is correct. There is massive money to be made by not only podiatrists doing these biopsies but by numerous pathology labs that are promoting these tests at our conventions and in journal ads.


 


At a seminar I attended, there was a med mal defense attorney lecturing about a case he was defending where the podiatrist was sued for doing a nerve biopsy on a diabetic who subsequently developed a severe infection from the wound created by the test. One of the questions asked of the defendant was why he needed to do the test in the first place and could the information it provided have been acquired from lesser invasive tests. Could the patients clinical history combined with nerve conduction studies have provided the same clinical information?


 


There is a time and a place for these biopsies, but we must all ask whether the benefit of doing them on every diabetic patient with neuropathy and/or reduced vascularity outweighs the risk.


 


Elliot Udell, DPM, Hicksville, NY

01/27/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2C



From: Paul Stepanczuk, DPM


 



I have performed many punch biopsies for nerve status over the last several years. I have never had a cellulitis problem or even delayed healing. Betadine prep is utilized and patients are given instructions for daily care until the area is fully healed.


 


The reimbursement is low; the biopsy is not performed for reimbursement. Instead, I use it to see if something as potentially costly as Metanx would be warranted over an extended period of time.


 


Paul Stepanczuk, DPM, Munster, IN


01/26/2017    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Joseph Borreggine, DPM, Steven Kravitz, DPM


 


I suggest that the Florida Licensing Board Members contact their local insurance agents to obtain an "umbrella policy" which will cover any litigation concerns on this matter. But typically, you are most likely indemnified by the state, and the state association may carry insurance for this type of issue. You may want to personally carry an umbrella policy of $2 million, which is not particularly expensive. These policies cover non-criminal acts.


 


Joseph Borreggine, DPM, Charleston, IL


 


Directors and officers insurance protect their board members in the event they are sued for the decisions they may on behalf of the organization they serve. Unfortunately, many state medical boards do not provide same. This is an issue and those volunteering to serve should consider requesting the organization of interest to do so. Pricing can vary, so it is helpful to investigate and purchase coverage for those services specifically provided by that organization.


 


Steven Kravitz, DPM, Executive Director, Academy of Physicians in Wound Healing

12/22/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Michael J. Trepal, DPM)


 


A recent posting by Dr. Dave Williams and subsequent responses raised the question of pharmacogenetic testing and therapy. At the New York College of Podiatric Medicine, we teach during the first year, a year's course in human genetics. The first semester is Introduction to Human Genetics followed by a second semester course in Molecular Biology/Molecular Genetics. In the first semester, students learn classical Mendelian genetics, with emphasis on genetic diseases caused by single gene defects. A genetic counselor from the Department of Genetics and Genomic Sciences, Icahn School of Medicine of Mount Sinai gives a guest lecture on how to take a pedigree and each student is required to draw their family's pedigree. In the second semester, emphasis is on precision/personalized medicine, including pharmacogenetics/genomics.  


 


The genetics of common complex diseases including Type 2 Diabetes is studied in depth. The Human Genome Project and ways to identify and study genes are explored. Lectures on use of DNA sequencing in clinical medine and pharmacogenetics are given by expert guest lecturers from the Department of Genetics and Genomic Sciences, Icahn School of Mount Sinai. The importance of genetic variants in determining the correct drug/dosage is discussed. The future role of precision/personalized medicine in podiatry is also emphasized. The course director at NYCPM is working with the Council of Faculties to include genetics in the podiatric medical school curriculum, and the working group has already decided on objectives. 


 


We believe that our year-long genetics course prepares our student well for future changes in Podiatric Medicine and introduces them to the concept of precision/personalized medicine including pharmacogentics.


 


Michael J. Trepal, DPM, NY, NY

12/19/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Dave Williams, DPM, Pete Harvey, DPM


 


I also have Practice Fusion. The easiest way I have found to upload images is to take a “screen shot” of my computer while viewing the image, then upload it into the Practice Fusion documents section.


 


Dave Williams, DPM, El Paso, TX


 


I would keep them separate. Be sure that each program is backed up daily, securely, and off-site. Then, run periodic checks to make sure the back-ups actually worked and can be recovered.


 


Pete Harvey, DPM, Wichita Falls, TX

12/16/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Simon Young, DPM


 


I know Dr. Feinberg and his skills well. I'm very proud of him. He will be an exceptional residency director and produce exemplory residents (our future colleagues) that we can all be proud of and who will advance our profession.


 


Simon Young, DPM, NY, NY

12/14/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Leonard  A. Levy, DPM, MPH


 


Dr. Dave Williams poses a question about pharmacogenetics. His question is very timely in that the medical genomic revolution is now underway, incited by the identification of the human genome more than a decade ago. Yet virtually nothing regarding genomics is found in the podiatric medical literature and little emphasis is provided on medical genomics in the podiatric medical education establishment. Genomics involves the interaction of multiple genes with the environment and is relevant to the prevention, diagnosis, and treatment of many of the most common diseases such as diabetes, cardiovascular conditions, cancer, and likely also to many podiatric medical conditions (eg., hallux valgus, club foot, etc.).


 


Also included is pharmacogenomics which identifies a drug dose specific to an individual rather than providing the same drug dose to all individuals (i.e., personalized or precision medicine). The time is long overdue for the podiatric medical profession to identify its role in medical genomics - the sooner the better.


 


Leonard  A. Levy, DPM, MPH, Ft. Lauderdale, FL

12/09/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Wenjay Sung, DPM, Tom Fusco, DPM


 


I understand the question of these Chinese vendors contacting various doctors to attend and speak at illegitimate conferences. I too have been solicited by various outlets for GFAC in China. Because I was unsure if some Chinese company hijacked Dr. Hardy's conference, I checked his website, but there isn't any updated info.  


 


So I implore Dr. Hardy to update the GFAC website, so there's no confusion. Right now, the only site with info for GFAC 2017 is bitcongress.com/GFAC2017/. This company BIT is notorious for fake conferences throughout China.


 


Wenjay Sung, DPM, Los Angeles, CA


 


I was at the conference held in Cleveland in 2016 and I can assure you it was very much a real conference. Great talks and a much better run conference, better talks than I have ever attended. Dr. Mark Hardy is the one still heading this up and they announced at the 2016 meeting that the 2017 would be held in China. I highly recommend anyone who wants to do some traveling to attend this conference. I have no affiliation with GFAC. 


 


Tom Fusco, DPM, Fort Walton Beach, FL

12/08/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: P David Applegate, DPM


 


I'm in the midst of opening a practice and have found a number of ways that technology can make for a nimble startup. With recent advances in cloud computing, an entirely cloud-based office is possible. Gone are the days of expensive server installations with costly monthly IT service contracts. With a modern EHR like Medi-Touch, much of the practice is handled via web browser. Patient registration and check-in can be handled entirely through the EHR, saving time and administrative costs over a traditional paper system. In addition, charting, surgical consent signing, and patient instruction on everything from stretching to wound care can all be done electronically.


 


Medi-Touch is what I've elected to go with, but there are a number of others out there like DrChrono and Practice Fusion that can be considered. The decision is entirely personal, but can be overwhelming. The same goes for digital x-rays. I recommend a good consultant to help you decipher between all of the options out there and aid you in negotiating competitive pricing. Again, the choice is entirely personal, but I've retained Cindy Pezza with Pinnacle Practice Achievement and have been very happy with the service I've received so far. 


 


P David Applegate, DPM, Houston, TX 

11/15/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2


RE: Orthotics and Insurance


From: Michael Forman, DPM


 


Our group handles orthotic devices in this manner:


1. The physician discusses his findings and proposed treatment (orthotics) with the patient.  A scan may or may not be done at that visit.


2. The physician sends a computerized note to our billing department with a diagnosis and code for the orthotic.


3. The billing people call the insurance company and determine coverage and payment.


4. The billing people then call the patient, explain the benefits, and then determine if they wish to go further.


5. If the orthotic devices are not fully covered, a 50% deposit must be made and the patient is told that the remainder must be paid before dispensing.


 


While this may sound like a long process, it is not, and can easily be accomplished in a small practice as well.


 


Michael Forman, DPM, Cleveland, OH

11/14/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2


RE: New Balance Shoe No Longer Made in USA


From: Robert S. Steinberg, DPM


 


New Balance's very popular 1260 running shoes are no longer made in the USA, but in China. New Balance failed to let anyone know. I had a patient complain to me that the shoe that I said was made in the USA, wasn't, I told him to take the shoe back, and complain. 


 


Robert S. Steinberg, DPM, Schaumburg, IL

11/12/2016    

RESPONSES/COMMENTS (NON-CLINICAL) - PART 2



From: Lori M. DeBlasi, DPM


 


I would like to thank Dr. Lee Rogers for his recent posting regarding Funding for Fellowships. His response, however, incorrectly stated “post graduate training must be accredited by the APMA and lead to board certification. Some podiatric fellowships are eligible to receive 50% funding for what is essentially a "4th year" of residency.”


 


The Council on Podiatric Medical Education (CPME) is an autonomous, professional accrediting agency designated by the American Podiatric Medical Association (APMA) to serve as the accrediting agency in the profession of podiatric medicine. As such, CPME, not APMA, approves residencies, fellowships, and continuing education providers, and accredits colleges of podiatric medicine.


 


Only CPME-approved fellowship programs may be eligible to receive federal funding; however, fellowships are not considered to be a fourth-year of residency. A podiatric fellowship is an educational program that provides advanced knowledge, experience, and training in a specific content area within podiatric medical practice. Fellowships, by nature of their specific content concentration, seek to add to the body of knowledge through research and other collaborative scholarly activities. Podiatric fellowship education is a component in the continuum of the educational process, and as such occurs after completion of an approved residency. The Council requires fellowships to afford training above and beyond that which is afforded during residency.


                                                                                                        


Additional information related to approval of fellowship programs, including a list of CPME-approved fellowship programs, is available at CPME’s website, select “Fellowships."


 


Lori M. DeBlasi, DPM, Chair, Council on Podiatric Medical Education
Rockwood Programs